Elsevier Previews Second Generation Inteleos at SLA DPHT
Now Inteleos is the Most Intuitive and Comprehensive Tool to Track Brand and Generic Drug Development
Amsterdam, 7 April 2008 – Elsevier, a leading scientific and healthcare publisher previewed the second generation of Inteleos today at the SLA Division of Pharmaceutical & Health Technology Spring meeting in St. Petersburg, Florida. A redesigned interface and the addition of US approved and tentatively approved generic drugs – seamlessly linked to the branded drug – gives business intelligence professionals unparalleled breadth and depth of content.
Other enhancements to Inteleos include expanded drug records with detailed development timeline overviews, drug properties, ongoing trials, competitor profiles and related news. The new Competitor Profile highlights products with the same mechanism of action or drug class in a simple interactive grid giving users a snapshot of the competitive landscape. Graphical timelines track progress through development to product launch, including actual and company predicted dates, so users can visualize the path to approval.
“Once again, Inteleos is setting the pace in business intelligence,” observes Gerry Stoia, President, Pharmaceutical Intelligence. “No other product on the market today links generics seamlessly back to the branded drug. This, in combination with the most in-depth FDA and EMEA filing data, makes Inteleos an indispensable tool for portfolio management.”
Building on the already heralded design, the new interface focuses on improved usability. The reorganization of the search fields and addition of Boolean operators gives users the flexibility to conduct quick or complex searches. Combined with the expansive filter options, Inteleos makes it easier to pinpoint data most relevant to a user’s needs.
“Inteleos makes finding, analyzing and organizing data easy and the quality of our content gives users confidence in business strategy and portfolio management decision making,” says Director of Inteleos, Julie Gordon. “With Inteleos, users can save time by getting straight to the information they need, to give their company a competitive advantage.”
For more information and a demonstration visit the booth or attend the Vendor Update presentations on 8 April at SLA DPHT. If you are unable to attend the conference contact our helpdesk at Inteleos@elsevier.com for further information.About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 305 1380